Mountain View,  CA 
United States
  • Booth: 926

CNS drug discovery with translatable neuroscience technology

High attrition rates in CNS clinical trials is an indication that current testing is failing to predict safety/efficacy of compounds. NeuCyte supports early phases of drug discovery programs as well as the investigation of MOAs for experimental compounds. Based on the SynFire® technology, our human neural in vitro platforms are uniquely suited for assessing relevant higher order electrophysiology readouts, which allow for a better predictor of drug efficacy and potential CNS safety/toxicology.

Send Email

Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".